CEPI (Coalition for Epidemic Preparedness Innovations) published its latest newsletter highlighting ongoing efforts to close the MPox vaccine access gap, the latest progress in the fight against Bundibugyo ebolavirus, funding for a fifth vaccine candidate, the initiation of another Phase 1 trial, and R&D news.

CEPI is an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. Central to CEPI’s pandemic-beating plan is the ‘100 Days Mission’ – its goal to develop safe, effective and accessible vaccines against new threats in just 100 days. CEPI is seeking $2.5 billion to execute CEPI 3.0, its 2027-2031 strategy, which will systematically reduce the likelihood, impact and cost of epidemics and pandemics by driving the 100 Days Mission towards an operational reality. Learn more at CEPI.net.